Usama Al-Qassab
Emory University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Usama Al-Qassab.
The Journal of Urology | 2013
Muta M. Issa; Usama Al-Qassab; John A. Hall; Chad W.M. Ritenour; John A. Petros; Jerry W. Sullivan
PURPOSE We describe a simple and effective method to reduce the risk of infection after prostate biopsy. MATERIALS AND METHODS A total of 1,642 consecutive prostate biopsy procedures during a 4-year period (2008 to 2012) were included in the study. Inclusion criteria consisted of pre-biopsy negative urine culture, bisacodyl enema and fluoroquinolone antibiotics (3 days). Formalin (10%) was used to disinfect the needle tip after each biopsy core. All patients were monitored for post-biopsy infection. The rate of infection was compared to that of a historical series of 990 procedures. Two ex vivo experiments were conducted to test the disinfectant effectiveness of formalin against fluoroquinolone resistant Escherichia coli, and another experiment was performed to quantitate formalin exposure. RESULTS Post-biopsy clinical sepsis with positive urine and blood cultures (quinolone resistant E. coli) developed in 2 patients (0.122%). Both patients were hospitalized, treated with intravenous antibiotics and had a full recovery without long-term sequelae. Mild uncomplicated urinary infection developed in 3 additional patients (0.183%). All were treated with outpatient oral antibiotics and had a complete recovery. The overall rate of urinary infection and sepsis using formalin disinfection was approximately a third of that of a prior series (0.30% vs 0.80%, p=0.13). Ex vivo experiments showed a complete lack of growth of fluoroquinolone resistant E. coli on blood and MacConkey agars after exposure to formalin. The amount of formalin exposure was negligible and well within the safe parameters of the Environmental Protection Agency. CONCLUSIONS Formalin disinfection of the biopsy needle after each prostate biopsy core is associated with a low incidence of urinary infection and sepsis. This technique is simple, effective and cost neutral.
International Braz J Urol | 2014
Ryan W. Dobbs; Lee A. Hugar; Louis M. Revenig; Usama Al-Qassab; John A. Petros; Chad W.M. Ritenour; Muta M. Issa; Daniel J. Canter
PURPOSE The incidence of lower urinary tract symptoms (LUTS) as the sole presenting symptom for bladder cancer has traditionally been reported to be low. The objective of this study was to evaluate the prevalence and clinical characteristics of newly diagnosed bladder cancer patients who presented with LUTS in the absence of gross or microscopic hematuria. MATERIALS AND METHODS We queried our database of bladder cancer patients at the Atlanta Veterans Affairs Medical Center (AVAMC) to identify patients who presented solely with LUTS and were subsequently diagnosed with bladder cancer. Demographic, clinical, and pathologic variables were examined. RESULTS 4.1% (14/340) of bladder cancer patients in our series presented solely with LUTS. Mean age and Charlson Co-morbidity Index of these patients was 66.4 years (range = 52-83) and 3 (range = 0-7), respectively. Of the 14 patients in our cohort presenting with LUTS, 9 (64.3%), 4 (28.6%), and 1 (7.1%) patients presented with clinical stage Ta, carcinoma in Situ (CIS), and T2 disease. At a median follow-up of 3.79 years, recurrence occurred in 7 (50.0%) patients with progression occurring in 1 (7.1%) patient. 11 (78.6%) patients were alive and currently disease free, and 3 (21.4%) patients had died, with only one (7.1%) death attributable to bladder cancer. CONCLUSIONS Our database shows a 4.1% incidence of LUTS as the sole presenting symptom in patients with newly diagnosed bladder cancer. This study suggests that urologists should have a low threshold for evaluating patients with unexplained LUTS for underlying bladder cancer.
Journal of Endourology | 2013
Adam B. Shrewsberry; Usama Al-Qassab; Michael Goodman; John A. Petros; Jerry W. Sullivan; Chad W.M. Ritenour; Muta M. Issa
PURPOSE The correct length of a ureteral stent is important in minimizing postplacement discomfort and stent migration. We describe and validate a method to accurately measure the ureteral length. MATERIALS AND METHODS The ureteral length in 48 patients undergoing ureteral stent placement for urolithiasis was measured by computed tomography (CT) (total thickness of axial slices between the ureteropelvic junction and ureterovesical junction) and adjusted up by 20%. The adjusted CT measurement of ureteral length was compared with direct intraoperative measurement using scatter plot and Pearson correlation coefficient. Correlation coefficients were also calculated between intraoperative ureteral length and various body habitus measurements such as the height, weight, and waist circumference. RESULTS Median patient age was 62 years. The median stone diameter was 7.5 mm (1-20). The ratio of left- to right-sided stones was 2:1. The stone location was in the proximal ureter in 45.8%, distal ureter in 37.5%, kidney in 10.4%, and midureter in 6.3%. Symptoms included adnominal/flank pain (93.8%) followed by nausea/vomiting (39.6%) and gross hematuria (16.7%). Median creatinine was 1.4 (0.8-3.6 mg/dl) and median WBC was 8.6 (2.8-17.6). The median ureteral length was 25.8 cm (19.2-29.4) on the CT scan and 25.5 cm (19.0-29.0) on the intraoperative measurement (p=0.57). The Pearson correlation coefficient between the two measurements was 0.979. In contrast, the height, weight, and waist circumference correlated poorly with intraoperative ureteral length measurements (r=0.34, 0.19, and 0.40, respectively). CONCLUSION CT-measured ureteral length adjusted up by 20% is a reliable method to accurately measure the true ureteral length. This method is superior to traditional indirect methods that rely on body habitus measurements.
Urology Practice | 2017
Ilan J. Safir; Vitaly Zholudev; Isabella M. Issa; Dean Laganosky; Louis Aliperti; Usama Al-Qassab; Jennifer Lindelow; Christopher P. Filson; Muta M. Issa
Introduction We evaluated the experience and preferences of patients undergoing hematuria consultation via teleurology compared to a conventional face‐to‐face clinic visit. Methods Patients evaluated for hematuria with teleurology or face‐to‐face clinic visit were surveyed regarding their experience and preferences. The survey consisted of 27 questions evaluating overall acceptance and satisfaction (8 questions), impact factors (17) and preference (2). Results A total of 450 patients participated in the survey at a 2‐to‐1 ratio (300 via teleurology, 150 via face‐to‐face visits). Overall, patient satisfaction level was higher with teleurology compared to face‐to‐face clinic visits (mean score 9.2 vs 8.4, p <0.0001). This finding was observed in all 8 domains (acceptance, efficiency, convenience, friendliness, quality of interview, communication and care, provider professionalism and privacy protection, all p <0.001). Transportation related issues were the most common underlying reason that influenced patient opinion, with at least 1 transportation factor being reported by 280 of 300 teleurology patients (93.3%) and 133 of 150 patients seen face‐to‐face (88.7%). Clinic operation and provider interaction factors similarly impacted patient satisfaction and preference. Time to access was significantly better for teleurology (12 days) compared to face‐to‐face clinics (72 days, p <0.001). Overall incidence of bladder cancer was 5.6% (25 of 450 patients), which was observed in 6.3% of the teleurology group (19 of 300) and 4.0% of the face‐to‐face group (6 of 150, p = 0.386). Conclusions Patients prefer teleurology to face‐to‐face clinic visits for the initial evaluation of hematuria. Teleurology positively impacts compliance and access by potentially eliminating common challenges facing patients, and by improving efficiency, convenience and flexibility.
Urology Practice | 2017
Ilan J. Safir; Vitaly Zholudev; Isabella M. Issa; Dean Laganosky; Louis Aliperti; Usama Al-Qassab; Jennifer Lindelow; Christopher P. Filson; Muta M. Issa
Introduction We evaluated the experience and preferences of patients undergoing hematuria consultation via teleurology compared to a conventional face‐to‐face clinic visit. Methods Patients evaluated for hematuria with teleurology or face‐to‐face clinic visit were surveyed regarding their experience and preferences. The survey consisted of 27 questions evaluating overall acceptance and satisfaction (8 questions), impact factors (17) and preference (2). Results A total of 450 patients participated in the survey at a 2‐to‐1 ratio (300 via teleurology, 150 via face‐to‐face visits). Overall, patient satisfaction level was higher with teleurology compared to face‐to‐face clinic visits (mean score 9.2 vs 8.4, p <0.0001). This finding was observed in all 8 domains (acceptance, efficiency, convenience, friendliness, quality of interview, communication and care, provider professionalism and privacy protection, all p <0.001). Transportation related issues were the most common underlying reason that influenced patient opinion, with at least 1 transportation factor being reported by 280 of 300 teleurology patients (93.3%) and 133 of 150 patients seen face‐to‐face (88.7%). Clinic operation and provider interaction factors similarly impacted patient satisfaction and preference. Time to access was significantly better for teleurology (12 days) compared to face‐to‐face clinics (72 days, p <0.001). Overall incidence of bladder cancer was 5.6% (25 of 450 patients), which was observed in 6.3% of the teleurology group (19 of 300) and 4.0% of the face‐to‐face group (6 of 150, p = 0.386). Conclusions Patients prefer teleurology to face‐to‐face clinic visits for the initial evaluation of hematuria. Teleurology positively impacts compliance and access by potentially eliminating common challenges facing patients, and by improving efficiency, convenience and flexibility.
Urology Practice | 2017
Ilan J. Safir; Vitaly Zholudev; Isabella M. Issa; Dean Laganosky; Louis Aliperti; Usama Al-Qassab; Jennifer Lindelow; Christopher P. Filson; Muta M. Issa
Introduction We evaluated the experience and preferences of patients undergoing hematuria consultation via teleurology compared to a conventional face‐to‐face clinic visit. Methods Patients evaluated for hematuria with teleurology or face‐to‐face clinic visit were surveyed regarding their experience and preferences. The survey consisted of 27 questions evaluating overall acceptance and satisfaction (8 questions), impact factors (17) and preference (2). Results A total of 450 patients participated in the survey at a 2‐to‐1 ratio (300 via teleurology, 150 via face‐to‐face visits). Overall, patient satisfaction level was higher with teleurology compared to face‐to‐face clinic visits (mean score 9.2 vs 8.4, p <0.0001). This finding was observed in all 8 domains (acceptance, efficiency, convenience, friendliness, quality of interview, communication and care, provider professionalism and privacy protection, all p <0.001). Transportation related issues were the most common underlying reason that influenced patient opinion, with at least 1 transportation factor being reported by 280 of 300 teleurology patients (93.3%) and 133 of 150 patients seen face‐to‐face (88.7%). Clinic operation and provider interaction factors similarly impacted patient satisfaction and preference. Time to access was significantly better for teleurology (12 days) compared to face‐to‐face clinics (72 days, p <0.001). Overall incidence of bladder cancer was 5.6% (25 of 450 patients), which was observed in 6.3% of the teleurology group (19 of 300) and 4.0% of the face‐to‐face group (6 of 150, p = 0.386). Conclusions Patients prefer teleurology to face‐to‐face clinic visits for the initial evaluation of hematuria. Teleurology positively impacts compliance and access by potentially eliminating common challenges facing patients, and by improving efficiency, convenience and flexibility.
The Journal of Urology | 2017
Usama Al-Qassab; Lindsey Hartsell; Joy Butterworth; John J DeCaro; Niall T.M. Galloway
RESULTS: Of 268 patients in the OAB database, 128 patients met inclusion criteria. Within the male subgroup, 26 of 47 men (44.7%) had successful treatment, compared to 73 of 81 women (90.1%). Within the male group, the factors significantly associated with SNS failure were mean volume at first urge on UDS (80.5ml in SNS failure vs. 126.5ml in SNS success) and smoking (SNS failure more likely to be current smokers, p 1⁄4 0.039). Similarly, on multivariate analysis only lower volume at first urge was statistically significantly associated with SNS failure (OR1⁄4.97, 95%CI 0.94-0.99). Within the female group, there were no statistically significant associations between measured variables and SNS success. Notably, mean volume at first urge on UDS was not statistically significantly associated with SNS failure, though there was a similarly large difference between groups (97.5ml in SNS failure compared to 136.0ml in SNS success). On multivariate analysis in the female group, there were no significant factors associated with SNS success. CONCLUSIONS: SNS is frequently successful at relieving OAB symptoms. The rate of success in men is significantly lower than in women, suggesting that SNS implantation is more effective in woman than men. The best predictor of success for male patients in this study was higher volume at first urge on UDS. Further study is needed to evaluate other predictors of SNS success and to further characterize differentiating characteristics between male and female patients with respect to overactive bladder treatment.
Case reports in oncological medicine | 2012
Kevin Baldie; Usama Al-Qassab; Chad W.M. Ritenour; Muta M. Issa; Adeboye O. Osunkoya; John A. Petros
We present a case of an ectopic renal tumor in a 61-year-old morbidly obese man with a pelvic kidney found after presenting with hematuria and irritative voiding symptoms. The mass, along with the ectopic kidney and ureter, was radically resected through an open operation that involved removing both them and the renal vessels from the underlying iliac vessels. Pathological analysis demonstrated an 8.3 cm papillary renal cell carcinoma (RCC) with oncocytic features, Fuhrman nuclear grade 3, with angiolymphatic invasion and negative margins. The patient has been recurrence-free for over four years since tumor resection.
Urology | 2013
Marla J. Wardenburg; Ryan W. Dobbs; Garrett Barnes; Usama Al-Qassab; Chad W.M. Ritenour; Muta M. Issa
The Journal of Urology | 2017
Usama Al-Qassab; C. Adam Lorentz; Dean Laganosky; Kenneth Ogan; Viraj A. Master; John Pattaras; Muta M. Issa; Christopher Keith; David L. Roberts; Michael R. Rossi; Sharon Bergquist; Jeremy Goecks; Rebecca S. Arnold; John A. Petros